Aytu BioPharma Acquires License to Develop DB102 for vEDS
Aytu BioPharma has acquired the option to license DB102 (enzastaurin), an investigational anti-tumor therapy with the potential to treat vascular Ehlers-Danlos syndrome, or vEDS. Denovo Biopharma, which holds worldwide rights to DB102 — originally developed as an oncology treatment — will continue to develop the oral therapy…